levetiracetam / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 185 Diseases   81 Trials   81 Trials   6476 News 


«12...70717273747576777879808182»
  • ||||||||||  levetiracetam / Generic mfg., fosphenytoin / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, HEOR:  ESETT: Established Status Epilepticus Treatment Trial (clinicaltrials.gov) -  Apr 20, 2019   
    P3,  N=478, Active, not recruiting, 
    Trial completion date: Dec 2018 --> Jun 2019 Recruiting --> Active, not recruiting | N=795 --> 478 | Trial completion date: Jul 2020 --> Oct 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation (clinicaltrials.gov) -  Apr 19, 2019   
    P=N/A,  N=172, Recruiting, 
    Recruiting --> Active, not recruiting | N=795 --> 478 | Trial completion date: Jul 2020 --> Oct 2019 Trial completion date: Sep 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Mar 2020
  • ||||||||||  levetiracetam / generics, topiramate / generics, propranolol / generics
    Clinical, Journal:  Migraine in Children: A Review. (Pubmed Central) -  Apr 14, 2019   
    Pediatrician should evaluate the child to exclude secondary cause of headache when indicated. They should have also proper knowledge and skills to manage a child having migraine to improve their quality of life and academic achievement.
  • ||||||||||  levetiracetam / generics
    Clinical, Journal, Monotherapy:  Vitamin B12 and Folate Status in Patients with Epilepsy Under Levetiracetam Monotherapy. (Pubmed Central) -  Apr 11, 2019   
    Treatment with levetiracetam in patients with epilepsy has no effect on the serum levels concentrations of homocysteine, vitamin B12, and folate. This medication is suggested for patients who use AEDs on a long-term basis and at high dosages.
  • ||||||||||  Trileptal (oxcarbazepine) / Novartis
    Clinical, Journal, HEOR:  Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy. (Pubmed Central) -  Apr 11, 2019   
    There is no evidence to suggest that regular monitoring of serum AED levels in pregnancy improves seizure control or affects maternal or fetal outcomes. Despite some similar characteristics of newer-generation antiepileptic drugs' effectiveness, levetiracetam stands out with better dynamic improvement of seizure severity and frequency and satisfactory tolerability; typical for pregabalin is a very good dynamic improvement of seizure severity and frequency mainly in patients with focal seizures, but a lower tolerability, and the main advantage of oxcarbazepine is a good tolerability, efficacy, however, is less satisfactory.
  • ||||||||||  levetiracetam / generics
    Journal:  Problems of juvenile myoclonic epilepsy. A view through the prism of time (Pubmed Central) -  Apr 10, 2019   
    However, the question of diagnosis is still a hard problem for neurologists. The questions to be resolved are: gender aspect of the disease, to what extent levetiracetam could be a drug of first choice and to what extent valproats could be replaced; monitoring of children born to mothers with JME, a role of paternal inheritance.
  • ||||||||||  zonisamide / generics, levetiracetam / generics, topiramate / generics
    Clinical, Journal:  The course and development of epilepsy in patients with typical variant of Rett syndrome and mutations (Pubmed Central) -  Apr 10, 2019   
    One patient with resistant epilepsy was treated with the combination of drugs (levetiracetam, topiramate, zonisamide, benzodiazepine) that led to stopping of seizures during night sleep and decrease in the frequency of daytime seizures by 50%. Further research of epilepsy and efficacy of antiepileptic drugs in Rett syndrome is required.
  • ||||||||||  allopregnanolone (LJPC-0712) / La Jolla Pharma
    Clinical, Journal:  Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults. (Pubmed Central) -  Apr 7, 2019   
    ...Most descriptive data are available for levetiracetam, phenytoin and valproate...Ketamine is an antagonist at this receptor and may prove efficient in some patients at later stages...Randomized controlled trials are needed to increase evidence for treatment of refractory and super-refractory status epilepticus, but there are multiple obstacles for realization. Hitherto, prospective multicenter registries for pharmacological treatment may help to improve our knowledge.
  • ||||||||||  Fycompa (perampanel) / Eisai
    Clinical, Journal:  Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy. (Pubmed Central) -  Apr 7, 2019   
    These data are expected to serve as a foundation upon which future therapeutics may be differentiated and assessed for potentially translatable efficacy in patients with refractory epilepsy. The present study suggests the utility of PER with concomitant LEV for children with drug-resistant epilepsy.
  • ||||||||||  levetiracetam / Generic mfg., ethosuximide / Generic mfg.
    Anti-epileptics influence gut microbiota: a possible relationship with drug resistance? () -  Apr 5, 2019 - Abstract #ECCMID2019ECCMID_810;    
    These preliminary results suggest that drugs other than antibiotics could impact on gut microbiota and that they should be considered as possible environmental factors modifying the microbial community. The observed changes, in turn, might influence host response to therapy.
  • ||||||||||  simvastatin / generics, glibenclamide / generics, amantadine / generics
    Biomarker, Journal:  Operation Brain Trauma Therapy: 2016 Update. (Pubmed Central) -  Apr 3, 2019   
    Operation brain trauma therapy suggests that levetiracetam merits additional pre-clinical and clinical evaluation and that glibenclamide and amantadine merit testing in specific TBI phenotypes. Operation brain trauma therapy has established that rigorous, multi-center consortia could revolutionize TBI therapy and biomarker development.
  • ||||||||||  levetiracetam / generics
    Review, Journal:  Development of neuropathology following soman poisoning and medical countermeasures. (Pubmed Central) -  Mar 29, 2019   
    ...Its potency was confirmed in systemic studies and is further enhanced when combined with levetiracetam...Evident advantages are seen when the same regimen exerts both powerful anticonvulsant and neuroprotectant efficacies. According to the results presented, the new strategy for establishing therapies against soman-induced seizures appears to be valid.
  • ||||||||||  oxaliplatin / generics, levetiracetam / generics
    Journal:  Evaluation of anticonvulsant and analgesic activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides. (Pubmed Central) -  Mar 29, 2019   
    ...We demonstrated that two molecules, DK-10 (11) and DK-14 (14) show higher anticonvulsant activity and similar safety profile in comparison with valproic acid and much higher in comparison with levetiracetam in the aforementioned test...For this purpose, the hot plate test, the formalin test, and the oxaliplatin-induced peripheral neuropathy model were performed...Compound DK-10 (11) had high affinity for voltage-gated sodium channels, whereas compound DK-11 (12) showed weak binding toward sodium and calcium voltage-gated channels and the NMDA receptor. As a result, hybrid compounds reported herein seem to be very promising broad spectrum anticonvulsant molecules with collateral analgesic activity.
  • ||||||||||  levetiracetam / generics
    Review, Journal:  Treatment of epilepsy for people with Alzheimer's disease. (Pubmed Central) -  Mar 28, 2019   
    Regarding efficacy and tolerability, no significant differences were found between LEV, PB and LTG. Large randomized controlled trials with a double-blind, parallel-group design are required to determine the efficacy and tolerability of treatment for epilepsy in people with AD.
  • ||||||||||  levetiracetam / generics
    Clinical, Journal:  New-Onset Geriatric Epilepsy in China: A Single-Center Study. (Pubmed Central) -  Mar 27, 2019   
    Autoimmune encephalitis is becoming an increasing risk factor of subsequent epilepsy in older people. Older patients with new epilepsy are more likely to respond to antiepileptic drugs, and drug-resistant epilepsy is uncommon.
  • ||||||||||  Edronax (reboxetine) / Pfizer
    Clinical, Journal:  Pharmacological Therapy in Panic Disorder: Current Guidelines and Novel Drugs Discovery for Treatment-resistant Patient. (Pubmed Central) -  Mar 26, 2019   
    Apart for their effectiveness, the aforementioned compounds were generally well tolerated compared to the standard available pharmacotherapy drugs, indicating their potential therapeutic usefulness for ambivalent and hypervigilance patient. Further strong clinical trials will provide an ample support to these novel compounds as an alternative monotherapy for PD treatment-resistant patient.
  • ||||||||||  Trileptal (oxcarbazepine) / Novartis
    Clinical, Journal:  Comparative efficacy of unique antiepileptic drug regimens in focal epilepsy: An exploratory study. (Pubmed Central) -  Mar 23, 2019   
    We identified two unique regimens more likely to be associated with ≥6 months of seizure freedom: levetiracetam/lamotrigine duotherapy and lamotrigine monotherapy. Polytherapy may be an effective alternative to monotherapy for patients with focal epilepsy and persistent seizures.
  • ||||||||||  levetiracetam / Generic mfg.
    Trial completion date, Trial primary completion date:  Levetiracetam in Early Psychosis (clinicaltrials.gov) -  Mar 22, 2019   
    P2,  N=32, Recruiting, 
    Although the majority of treated patients received AED monotherapy consistent with guidelines, suboptimal rates of AED treatment and persistence of first-line treatment after initial epilepsy diagnosis suggest that efforts are needed to improve patient care. Trial completion date: Feb 2019 --> Jun 2019 | Trial primary completion date: Feb 2019 --> Jun 2019
  • ||||||||||  lacosamide / Generic mfg., levetiracetam / Generic mfg.
    Enrollment open:  Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) -  Feb 5, 2019   
    P2,  N=232, Recruiting, 
    Trial completion date: Feb 2019 --> Jun 2019 | Trial primary completion date: Feb 2019 --> Jun 2019 Not yet recruiting --> Recruiting
  • ||||||||||  levetiracetam / Generic mfg.
    Trial termination:  Keppra for Cervical Dystonia (clinicaltrials.gov) -  Nov 23, 2018   
    P2,  N=17, Terminated, 
    Trial primary completion date: Aug 2018 --> May 2020 | Trial completion date: Mar 2032 --> Oct 2034 Suspended --> Terminated; Sponsor decided to stop enrollment to review data.